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SUMMARY – The aim of this article is to present two Slovenian chorea-acanthocytosis (ChAc) 
siblings with an unusual predominantly dystonic ChAc phenotype. For diagnostic purposes, the 
genomic DNA was screened for VPS13A mutations. Movement disorder was evaluated and scored 
according to the Dystonia Movement and Disability Scale (DMDS) in order to evaluate the effects 
of L-dopa on dystonia. Brain imaging was performed with the use of magnetic resonance imaging 
scan and 99m Tc-ethyl cysteinate dimmer single photon emission computed tomography (Tc-ECD 
SPECT). Clinical neurological examination disclosed gait dystonia. Marked swallowing difficulty 
due to tongue and feeding dystonia was observed. Both siblings were found to be heterozygous for 
a substitution in exon 22 (c.2191C>T) and for a deletion in exon 35 (c.3995_3996delinsA) leading 
to mutation in VPS13A. After being administered L-dopa for three months, both subjects showed 
significant symptomatic improvement documented by reduced DMDS scores. It is concluded that 
VPS13A mutation testing may improve diagnosis of dystonia and recognition of atypical ChAc 
phenotypes. It seems that L-dopa could be effective in the treatment of dystonia due to VPS13A 
mutations.
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Introduction
Chorea-acanthocytosis (ChAc) is a rare, heredi-
tary, neurodegenerative disease marked by phenotypic 
heterogeneity. It manifests as a mixed movement dis-
order, including chorea and parkinsonism. Dystonia is 
an unusual clinical presentation of the disease. Other 
features include seizures, neuropathy, myopathy, au-
tonomic features, dementia and psychiatric symp-
toms1. The main neuropathologic feature of ChAc is 
degeneration of the striatum2. VPS13A is the only 
currently known gene to be associated with ChAc2. 
Thus, testing for VPS13A mutation may be helpful in 
diagnostic evaluation of various movement disorders 
such as dystonia.
Dystonia which is characterized by involuntary, 
sustained muscle contractions affecting one or more 
sites of the body, frequently causing twisting and re-
petitive movements or abnormal postures is an un-
common clinical form of ChAc. In the early stages of 
ChAc, the phenotype often comprises dysphagia and 
tongue dystonia and appears quite indicative of the 
disease3. Eating can also be impaired as tongue and 
throat twitches can interfere with chewing and swal-
lowing of the food. People with ChAc may uncontrol-
lably bite their tongue, lips, and inside of the mouth. 
In this article, we present two Slovenian VPS13A 
mutation confirmed ChAc siblings, in whom an un-
usual, predominantly dystonic ChAc phenotype with 
mild frontal type dementia and elements of parkin-
sonism was observed. In addition, we noticed allevia-
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tion of dystonia after L-dihydroxyphenylalanine (L-
dopa) administration.
Case Report
The patients were first examined at 44 and 43 years 
of age, due to gait instability and involuntary move-
ments that had started in their late thirties. Detailed 
clinical neurological examination was performed, fol-
lowed by physical examination and laboratory tests to 
exclude somatic pathology that could lead to the for-
mation of acanthocytes. Movement disorder was eval-
uated and scored according to the Dystonia Movement 
and Disability Scale (DMDS)4. Clinical neurological 
examination disclosed gait dystonia, which consisted 
of neck retroflexion with hyperlordosis, as well as in-
version of the foot of the advancing leg and flexion 
of the opposite knee and foot when walking. Due to 
gait instability, the patients could barely walk a few 
steps. The female patient in particular presented with 
marked swallowing difficulties due to tongue and 
feeding dystonia. Also, she developed an interest-
ing feeding technique by pushing parts of solid food 
into her throat with the use of her fingers. General-
ized dystonia affected her face, trunk, extremities and 
allowed her only scarce moments of independence. 
When in distress, choreatic truncal movements were 
observed in the male patient. The female patient had 
developed movement disorder about two years earlier 
than her brother and was first seen by a neurologist 
at about one and a half year later. Therefore, she pre-
sented with consistently worse DMDS scores (Fig. 
1A). In addition, signs of parkinsonism were observed 
in her, including mask like face, stooped posture and 
bradykinesia. Cognitive deficits suggestive of frontal 
lobe dementia with psychomotor slowing were re-
vealed by cognitive clinical examination. Worsening 
of clinical features and the lack of chorea led us to the 
question of whether the dystonia observed in the sib-
lings might respond to L-dopa treatment. Following 
daily administration of L-dopa/benserazide 100/25 
t.i.d. for 3 months, both subjects showed significant 
symptomatic improvement documented by reduced 
DMDS scores (Fig. 1A). Improved ambulation was 
the most striking effect of L-dopa treatment. The 
patients were able to walk unaided for approximately 
600 meters and were able to go shopping in the nearby 
grocery store. 
After 18 months of successful L-dopa treatment, 
dystonia in the female worsened and she gradually 
deteriorated to her pretreatment status. As a result, 
L-dopa administration was discontinued (Fig. 1A). In 
contrast, her brother showed stable improvement over 
3 years of therapy. Further clinical course in the fe-
male was relentlessly progressive with development of 
further dyskinesia. She died in a nursing home, most 
likely due to terminal pneumonia about 4 years after 
the first examination. The male patient remained free 
of dyskinesia and independent for about eight and half 
years after the first examination. However, parkin-
Fig. 1. Effects of L-dopa treatment on the dystonia-parkinsonism phenotype of chorea-acanthocytosis: graphs depict 
dystonia movement and dystonia disability scores before and up to 24 months after initiation of L-dopa treatment (A); 
representative 99mTc-ECD SPECT brain images showing symmetrically decreased radiolabeling in the frontal and 
temporal lobes and in the basal ganglia in the male and female in comparison with an age-matched healthy control, before 
and after 18-month L-dopa treatment (B).
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sonian features and dysphagia were progressive. He 
was eventually admitted to a nursing home, where he 
suffered from food aspiration, was resuscitated, and 
consequentially spent the last months of his life in a 
vegetative state.
A written informed consent for publication of the 
data was obtained from the patients’ closest relatives 
(two brothers and a sister). 
Methods
Electromyography (EMG) was performed to con-
firm the peripheral neuropathic disorder. Brain imag-
ing was performed with the use of magnetic resonance 
imaging scan (MRI, GE Signa MR tomograph, TR 
3000 ms, TE 24 ms, slice thickness 5 mm) and 99m 
Tc-ethyl cysteinate dimmer single photon emission 
computed tomography (99m Tc-ECD SPECT, Mul-
tispect 2, Siemens, 180 projections, 1 frame/2 degrees, 
128x128 matrix, slice thickness 7.2 mm). The patients’ 
parents and siblings were free from any neurological 
disorders. Genomic DNA was screened for VPS13A 
mutations using techniques described previously5. 
Results
Magnetic resonance imaging (MRI) diagnostic 
work-up disclosed symmetric atrophy of the heads of 
the caudate nuclei. On 99m Tc-ECD SPECT, sym-
metrically decreased radiolabeling indicating a de-
crease in the cerebral blood flow and metabolism in 
the frontal, temporal lobes, and basal ganglia (Fig. 
1B, without L-dopa) was observed. Control 99m Tc-
ECD SPECT performed 18 months after treatment 
initiation showed a 30% decrease in radiolabeling of 
the basal ganglia compared to the pretreatment values 
in the female, but showed virtually no change in the 
male (Fig. 1B, 18 months of L-dopa). 
Abnormally high percentages of acanthocytes in pe-
ripheral blood were detected, comprising 63% and 75% 
of total red blood cells in the female and male, respec-
tively. This led us to further screening for VPS13A gene 
mutations. Both siblings were found to be heterozygous 
for a substitution in exon 22 (c.2191C>T), leading to 
a nonsense mutation (p.R731X), and for a deletion in 
exon 35 (c.3995_3996delinsA), leading to a frameshift 
mutation (p.F1332X), in VPS13A (Fig. 2), as previously 
reported5,6 (Fig. 2B). A predominantly sensory axonal 
neuropathy was also found on EMG.
Discussion
Chorea-acanthocytosis is an autosomal recessive 
disorder (Fig. 2A) caused by mutations in the vacuolar 
protein sorting 13 homolog A (VPS13A) gene1. The 
mutations have been shown to abrogate or severely re-
duce expression of the VPS13A protein product, chor-
ein. Chorein is assumed to be involved in intracellular 
Fig. 2. Pedigree of the Slovenian kindred exhibiting autosomal recessive inheritance of chorea-acanthocytosis: the affected 
siblings are shown in red (A); identification of VPS13A mutations. Sequence chromatograms from the female and control 
DNA are displayed. Location of 2191C>T and 3995_3996delinsA mutations are marked by arrows. These mutations 
were also detected in the male patient; for exon 35, the reverse (antisense) strand DNA sequence is displayed (B).
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trafficking of a number of transmembrane proteins. 
However, its function remains largely unknown7,8. 
VPS13A mutations result in a movement disorder, 
which usually takes the form of choreatic dyskine-
sias, typically found in conjunction with acanthocytic 
red blood cells (RBC)9. The clinical manifestations of 
VPS13A mutations are variable and include progres-
sive movement abnormalities ranging from chorea to 
parkinsonism10, with dystonia observed infrequent-
ly9,10. Muscular weakness due to myopathy/polyneu-
ropathy is typically associated, as we diagnosed in our 
patients. Cognitive impairment, personality changes 
and epilepsy may accompany and/or precede move-
ment abnormalities11,12. A variety of psychiatric symp-
toms may also occur10,13. ChAc phenotypes are there-
fore remarkably heterogeneous and their pathogenesis 
is obscure. As a result, current therapeutic approaches 
are restricted to the treatment of symptoms. The mu-
tant VPS13A genotype in the patients described here 
resulted in a predominantly dystonic phenotype of 
ChAc with elements of parkinsonism. This particular 
phenotype, in conjunction with the significant hetero-
geneity of clinical phenotypes produced by other VP-
S13A mutations10, suggests that VPS13A mutations 
not infrequently manifest with phenotypes where 
chorea develops years to decades after the onset of 
the disease11-13. As shown in this article, patients may 
even develop movement disorder that never progresses 
to obvious chorea. Patients with late onset or absent 
chorea may not undergo chorein or VPS13A muta-
tion testing until late in the disease course. Current 
understanding of early ChAc phenotypes may there-
fore be biased towards phenotypes exhibiting obvious 
chorea in the early stage of the disease. The diagnosis 
of ChAc may, however, be confirmed by measuring 
chorein levels in RBC membranes of ChAc patients 
and/or by demonstrating VPS13A mutations7. 
Several forms of dystonia beyond L-dopa respon-
sive dystonias in the strict sense have been reported 
to benefit from L-dopa, which is probably due to the 
metabolic defect in dopamine synthesis14,15. However, 
this strategy was not useful in the treatment of id-
iopathic dystonia16.  The dystonia of both our ChAc 
patients responded favorably to L-dopa treatment. In 
the female patient, however, the effect was short-term, 
with eventual reappearance of dystonic dyskinesias. 
Studies in Parkinson’s disease patients have sug-
gested that L-dopa might be beneficial and even slow 
down the progression of Parkinson’s disease, but it 
may also encourage early motor complications, such as 
dystonic dyskinesias. The mechanism of these effects, 
however, remains obscure17. It seems that L-dopa in 
addition to increasing dopamine synthesis might have 
an impact on intracellular trafficking of transmem-
brane proteins, which consequently alter their modi-
fying role of striatal G-protein coupled receptors and 
therefore might favor the expression of dyskinesia18,19. 
The symptoms that present in ChAc patients shar-
ing the same mutation may be heterogeneous12 and 
may resemble parkinsonism, ‘peak dose’, as well as 
‘off period’ dyskinesia in Parkinson’s disease patients. 
According to experimental data, it might be due to 
alteration in the processes of intracellular trafficking 
of different, unrelated transmembrane proteins influ-
enced by chorein7. We speculate that in the female pa-
tient, the ‘off period’ dyskinesia developed again after 
initial improvement with L-dopa therapy, due to the 
longer disease course and consequently more devel-
oped striatal pathology, whereas in the male with less 
developed striatal pathology, the effect of increased 
dopamine synthesis was beneficial for a prolonged pe-
riod of time. Parkinsonism, which in ChAc patients 
is not reactive to L-dopa20, took its further progressive 
course.
Our propositions are in line with the reports re-
vealing dopaminergic dysfunction by neuroimaging 
and neuropathologic analysis of brains obtained from 
ChAc patients and showing striatal as well as nigral 
atrophy10,21. In addition, depletion of dopamine and 
its metabolites was found in most brain areas, most 
notably in the striatum of ChAc patients22. The 
clinical course in our patients was paralleled by 99m 
Tc-ECD SPECT neuroimaging that revealed almost 
unchanged regional cerebral perfusion over 18-month 
L-dopa treatment in patient K.A. Interestingly, clini-
cal deterioration in patient R.M. after 18-month L-
dopa treatment was accompanied by a 30% decrease 
in regional cerebral perfusion.  
In conclusion, our study suggests that the use of 
VPS13A mutation testing may improve diagnosis of 
dystonia and recognition of atypical ChAc pheno-
types. L-dopa may be beneficial in the symptomatic 
treatment of dystonia due to VPS13A mutations. 
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Sažetak
DISTONIJA KAO MANIFESTACIJA KOREA-AKANTOCITOZE 
J. Kobal, C. Dobson-Stone, A. Danek, V. Fidler, B. Zvan i M. Zaletel
Prikazuje se dvoje slovenskih bolesnika, brat i sestra, s koreom-akantocitozom, s neuobičajenim pretežito distoničnim 
fenotipom korea-akantocitoze. Proveden je dijagnostički probir genomske DNA na mutacije VPS13A. Poremećaj kretanja 
procijenjen je i ocijenjen prema Dystonia Movement and Disability Scale (DMDS) kako bi se procijenili učinci L-dopa na 
distoniju. Slikovni prikazi mozga napravljeni su pomoću magnetske rezonance i Tc-ECD SPECT (99m Tc-ethyl cysteinate 
dimmer single photon emission computed tomography). Klinički neurološki pregled otkrio je distoniju hoda. Zapažene su 
znatne teškoće pri gutanju zbog distonije jezika i distonija hranjenja. I brat i sestra bili su heterozigotni za supstituciju u 
eksonu 22 (c.2191C>T) i za deleciju u eksonu 35 (c.3995_3996delinsA), koje uzrokuju mutaciju u VPS13A. Nakon da-
vanja L-dopa kroz tri mjeseca oboje je pokazalo značajno poboljšanje simptoma, što je dokumentirano sniženim zbirom 
na DMDS. Zaključuje se da testiranje na mutaciju VPS13A može pomoći u dijagnosticiranju distonije i prepoznavanju 
atipičnih fenotipova korea-akantocitoze. Čini se da bi L-dopa mogla biti učinkovita u liječenju distonije uzrokovane mu-
tacijama VPS13A.
Ključne riječi: Neuroakantocitoza; Distonija; Korea; VPS13A testiranje; Levodopa
